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Abstract
Anthrax lethal toxin (LT) induces vascular insufficiency in experimental animals through unknown mechanisms. In this study,
we show that neuronal nitric oxide synthase (nNOS) deficiency in mice causes strikingly increased sensitivity to LT, while
deficiencies in the two other NOS enzymes (iNOS and eNOS) have no effect on LT-mediated mortality. The increased
sensitivity of nNOS2/2 mice was independent of macrophage sensitivity to toxin, or cytokine responses, and could be
replicated in nNOS-sufficient wild-type (WT) mice through pharmacological inhibition of the enzyme with 7-nitroindazole.
Histopathological analyses showed that LT induced architectural changes in heart morphology of nNOS2/2 mice, with
rapid appearance of novel inter-fiber spaces but no associated apoptosis of cardiomyocytes. LT-treated WT mice had no
histopathology observed at the light microscopy level. Electron microscopic analyses of LT-treated mice, however, revealed
striking pathological changes in the hearts of both nNOS2/2 and WT mice, varying only in severity and timing. Endothelial/
capillary necrosis and degeneration, inter-myocyte edema, myofilament and mitochondrial degeneration, and altered
sarcoplasmic reticulum cisternae were observed in both LT-treated WT and nNOS2/2 mice. Furthermore, multiple
biomarkers of cardiac injury (myoglobin, cardiac troponin-I, and heart fatty acid binding protein) were elevated in LT-treated
mice very rapidly (by 6 h after LT injection) and reached concentrations rarely reported in mice. Cardiac protective nitrite
therapy and allopurinol therapy did not have beneficial effects in LT-treated mice. Surprisingly, the potent nitric oxide
scavenger, carboxy-PTIO, showed some protective effect against LT. Echocardiography on LT-treated mice indicated an
average reduction in ejection fraction following LT treatment in both nNOS2/2 and WT mice, indicative of decreased
contractile function in the heart. We report the heart as an early target of LT in mice and discuss a protective role for nNOS
against LT-mediated cardiac damage.
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Introduction
Anthrax toxin, the major virulence factor of Bacillus anthracis,
consists of three polypeptides: Edema Factor (EF), Lethal Factor
(LF) and Protective Antigen (PA). LF is toxic in animal models
when combined with the receptor-binding PA, which facilitates LF
entry into cells [1]. Mouse strains have been shown to have a
range of susceptibilities to anthrax lethal toxin (LT, the
combination of PA and LF) [2] and succumb displaying atypical
shock-like symptoms without classic systemic hemorrhagic man-
ifestations [3]. LT induces rapid lysis of macrophages isolated from
some inbred mouse strains, and in vivo macrophage sensitivity to
LT can contribute to a cytokine storm and more rapid death in
certain strains. LT susceptibility, however, is distinctly indepen-
dent of macrophage sensitivity in other mouse strains [2]. LT-
induced events lead to death of mice in 2–3 days, while some rat
strains die in as little as 37 min when subjected to the same dose of
toxin [4,5]. This extremely rapid death in rats, which is dependent
on PA and transport of LF to the cellular cytoplasm, is
accompanied by a rapid accumulation of pleural fluid. Although
LF is known to cleave most of the mitogen-activated protein kinase
kinases (MAPKKs) [6,7], the molecular basis for LT-mediated
effects leading to shock in animals is currently unknown.
Nitric oxide (NO) is one of the most potent modulators of
vascular function in vivo and its production by NO synthases is
often highly increased during infections. The role of NO in LT- or
Bacillus anthracis-mediated pathogenesis has been investigated in a
number of studies. We previously tested inducible NO synthase
(iNOS) knockout mice (iNOS2/2) for susceptibility to LT and
found no difference in LT sensitivity relative to WT controls [2].
Surprisingly, iNOS2/2 mice also display similar susceptibility to
wild type controls in B. anthracis infection in mice [8]. In the rat LT
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circulatory shock with no associated changes in NO concentra-
tions [9]. While it has been reported that B. anthracis infection can
induce NO production in macrophages [10], LT actually has
inhibitory effects on NO induction by iNOS through many classic
stimuli such as lipopolysaccharide (LPS) [11]. LT itself does not
induce NO production in macrophage cell lines or peritoneal
macrophages and changes in NO circulatory levels were not
detected in LT-treated mice ([2] and data not shown).
The rapid and impressive changes that occur in NO
concentrations during bacterial infections are generally attributed
to the action of the inducible NO synthase isoform (iNOS). After
previous studies did not identify a role for iNOS in LT-mediated
effects [2], we chose to extend these studies to examine the role of
the constitutive NO synthases in LT-mediated pathogenesis.
Knockout mice lacking either endothelial NO synthase (eNOS)
or neuronal NO synthase (nNOS) have been useful for delineating
the roles of these important enzymes in NO-mediated events. In
the current study we report on the increased sensitivity of
nNOS2/2 mice to toxin when compared to iNOS2/2 and
eNOS2/2 mice, as well as to WT mice, suggesting a protective
role for nNOS in LT-mediated pathogenesis. Histopathological,
electron microscopy and heart biomarker analyses revealed that
LT results in rapid and striking pathology in the murine heart and
that nNOS may provide a degree of protection against LT-
mediated cardiac effects.
Results
nNOS2/2 mice have significantly increased sensitivity to
LT
Because LT targets the vasculature [3,9,12,13] and NO plays a
key role in control of vascular function, we previously tested
iNOS2/2 mice, but found no change in LT sensitivity [2]. To
determine whether the other NO synthases control LT suscepti-
bility, we compared iNOS, eNOS and nNOS2/2 mice and their
corresponding parental strains to challenge with a single dose of
LT (100 mg). The iNOS2/2 and eNOS2/2 mice did not show
any significant difference in susceptibility to LT compared to their
C57BL/6J (Figure 1A) or B6.129SF2/J (data not shown) parental
controls, with over 50% of the animals succumbing by 120 h
(Figure 1A and data not shown). However, the nNOS2/2 mice
were uniquely sensitive to LT with 50% of mice succumbing by
30 h. More than 95% of these animals were dead by 48 h after a
single challenge of LT (100 mg). At the lower challenge dose of
40 mg, 80% of the nNOS2/2 mice died between 50 and 108 h
(Figure 1B), while the 30% of control animals that succumbed only
started doing so at 108 h. In general, malaise symptoms were
apparent in toxin-challenged nNOS mice as early as 12 h after
injection while control animals rarely showed signs of malaise until
60 h. Thus, nNOS-deficient mice were clearly more sensitive to
LT than their wild type counterparts. Treatment with PA alone or
PA and enzymatically inactive LF is not lethal to mice (data not
shown).
Figure 1. nNOS2/2 mice are more susceptible to LT. nNOS2/2,
eNOS2/2, iNOS2/2, and C57BL6/J mice were treated with LT ((A)
100 mg IP, or (B) 40 mg IP) and monitored for survival. The experiment
shown in (A) represents data from four independent toxin challenge
experiments that included all four mouse strains. Eleven additional
independent toxin challenge experiments that included controls and
nNOS2/2 mice also yielded the same results. The n values for panel (A)
are as follows: C57BL/6J (n= 36), nNOS2/2 (n=33), eNOS2/2 (n=
16), iNOS2/2 (n=21). Logrank test P-values for comparison of nNOS2/
2 mouse survival curves with each of the eNOS2/2, iNOS2/2, and
C57BL/6J mouse survival curves are ,0.0001 for panel A. The
experiment in (B) (n=10 for each strain) is a single experiment
representative of two independent experiments.
doi:10.1371/journal.ppat.1000456.g001
Author Summary
Injection of pure anthrax lethal toxin (LT) at the levels
found in terminally-ill, anthrax-infected animals induces an
atypical vascular collapse in several experimental animals
without the associated hemorrhagic manifestations and
disseminated intravascular coagulopathies seen in bacte-
ria-induced shock states. Nevertheless, LT alone produces
the pleural edema that is a classic manifestation of anthrax.
All the histopathological changes previously observed in
LT-treated mice can be explained as predictable sequelae
of vascular insufficiency. In this report, electron micro-
scopic analysis was used to identify rapid and striking
pathological changes in endothelial cells, myocytes,
mitochondria, and the sarcoplasmic reticulum cisternae
in the hearts of LT-challenged mice. These morphological
changes were paralleled by release of very high levels of
multiple cardiac injury biomarkers. LT-induced patholog-
ical changes occurred earlier and with markedly higher
severity in nNOS knockout mice compared to wild-type or
iNOS or eNOS knockout mice, reflecting the well-estab-
lished role of nNOS in maintenance of cardiac function,
and suggesting that nitric oxide produced by nNOS
counteracts the damage induced by LT.
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altered macrophage sensitivity or cytokine responses
We previously showed that while macrophage sensitivity to LT
in mice is not a direct correlate to animal sensitivity for a number
of strains, the presence of sensitive macrophages in the normally
more resistant C57BL/6J strain (which harbors LT-resistant
macrophages) made the mice as susceptible as Balb/cJ mice
(which harbor LT-sensitive macrophages) [2]. Thus in some
strains, macrophage sensitivity contributes to a more rapid onset of
malaise and death. Macrophage sensitivity in mice was also shown
to correlate with a rapid release of IL-1b from lysed circulating
macrophages, and a subsequent rapid induction of a number of
different cytokines over a 6 h period, followed by drop to baseline
levels by 24–30 h [2,3]. We tested whether nNOS could
potentially play a role in macrophage sensitivity to LT resulting
in the sensitization of mice. Figure 2A shows that macrophages
from nNOS2/2 mice are resistant to LT in a manner similar to
the parental C57BL/6J strain. Accordingly, no cytokine burst (IL-
1b, MIP-1, IL-6) was observed in these animals following LT
treatment (Figure 2B and data not shown), indicating that nNOS
deficiency was not leading to increased LT sensitivity through
altered inflammatory cytokine responses as has been suggested for
other shock models [14].
7-nitroindazole sensitizes wild-type mice to LT
We next asked if the selective nNOS inhibitor 7-nitroindazole
(7-NI) could replicate the sensitivity phenotype seen in nNOS2/2
mice. Groups of C57BL/6J mice were treated with 25 mg/kg or
50 mg/kg of 7-NI once a day for three days prior to challenge with
a single dose of LT (100 mg IP) on the third day. Control C57BL/
6J and nNOS2/2 groups were treated with the vehicle (10%
DMSO) used for drug delivery, or with PBS on the same schedule
and challenged with LT. A final (fourth) dose of drug or vehicle
was also given on the day following toxin challenge. Figure 3
shows the experimental schedule (top panel) and the survival
results, which clearly show that 7-NI sensitizes the WT mice to
LT. Sensitivity levels almost identical to nNOS2/2 mice were
seen following 7-NI treatment of WT mice.
Histopathology analysis of LT-treated nNOS2/2 mice
LT treatment of mice generally produces few histopathological
changes besides those considered to be sequelae of the vascular
insufficiency [3]. We previously described changes in tissues such as
the liver or bone marrow in mice as being due to compromised
oxygenation, since the severity increased with distance from blood
vessels [3]. To see if any novel pathological events occur in
nNOS2/2 mice treated with LT, we performed histopathological
analyses on H&E-stained lung, heart, aorta, brain, kidney, spleen,
liver and bone marrow obtained from knockout and control mice
treated with LT for 7 h, 15 h, and a range of times between 23–
36 h when different grades of malaise severity were noted. At all
these times the C57BL/6J mice used as matching time point
controls were not ill, while nNOS2/2 mouse malaise grades
ranged from (+)t o( +++=moribund). No histopathological changes
were found in LT-treated mice compared to PA-treated, PBS-
treated or untreated controls for the WT strain in any tissues. The
only LT-induced pathological changes found in the nNOS2/2
micewere in the hearts of mice having marked malaise symptoms at
later time points. The hearts from these LT-treated nNOS2/2
mice showed novel inter-fiber vacuole-like spaces in the cardiac
muscle tissue, with grainy punctuate staining in the tissue, possibly
indicative of altered (swollen) mitochondria. The spaces also
appeared to hold granular content which were suggestive of
releasedmitochondriaorcell debris(Figure4).LT-treated WTmice
didnot indicate any histopathological changes atanytime point and
resembled the untreated nNOS2/2 mice shown in Figure 4
throughout the course of the experiment (data not shown).
Because apoptosis has been shown to be modulated by NO in
the heart [15,16], we asked whether the heart tissue changes
observed in toxin-treated nNOS2/2 mice could be accompanied
by apoptotic cell death. TUNEL staining, however, indicated that
with the exception of the occasional lone TUNEL-positive cell (in
this case in the untreated mouse heart), apoptosis was not observed
in the LT-treated hearts (Figure 4). Because nNOS has been
shown to be up-regulated as a protective response in hypoxia and
shock [17,18], we immunostained for nNOS, to see if LT
treatment actually resulted in any change in the levels of this
enzyme. Strong staining was observed in the hearts of both PA-
treated, untreated and LT-treated mice, with no differences
evident (data not shown). Myeloperoxidase staining was used to
assess neutrophil infiltration (often associated with cardiac
damage), and cytochrome c oxidase I (COX1) staining was used
to investigate potential loss of mitochondria from cardiomyocytes.
No differences between the LT-treated and untreated samples
were seen for either of these stains. Of course the COX1 was only
Figure 2. nNOS2/2 mouse macrophages are not sensitive to LT
and nNOS2/2 mice do not release IL-1b following LT treatment.
(A) BMDMs derived from C57BL/6J, nNOS2/2 and Balb/cJ mice were
treated with varying doses of LT for 2 h and viability assessed by MTT
staining. Percent viability is expressed relative to untreated controls. (B)
Balb/cJ, C57BL/6J, and nNOS2/2 mice were treated with LT (100 mgI P )
and bled at four time points after LT injection (n=2 mice/time point). IL-
1b level in serum was assessed by ELISA.
doi:10.1371/journal.ppat.1000456.g002
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of respiratory function in the hearts. Masson trichrome staining
(for cardiac fibrosis and necrosis) also did not yield significant
differences associated with LT treatment in a blind-test analysis
(data not shown). Altogether, with the exception of the novel inter-
fiber vacuole-like spaces seen in LT-treated nNOS2/2 hearts,
light microscopy did not show any immune cell infiltration or
pathological changes.
Figure 3. 7-NI sensitizes nNOS-sufficient WT mice to LT. C57BL/6J or nNOS2/2 mice were treated with 7-NI (50 mg/kg or 25 mg/kg), PBS, or
drug vehicle (10% DMSO) according to the schedule shown in the top panel. LT was administered on day 3 and animals were followed for survival
(n=5 for each group). Data is representative of two similar experiments. Logrank test P-values were ,0.005 when comparing survival curves for
C57BL/6J /25 mg/kg+LT, C57BL/6J /50 mg/kg+LT, nNOS2/2/PBS+LT, and nNOS2/2/vehicle+LT mouse groups to either the C57BL/6J/PBS or C57BL/
6J/vehicle mouse groups.
doi:10.1371/journal.ppat.1000456.g003
Figure 4. Histopathological analysis of LT-treated hearts in nNOS2/2 mice. Left and central panels shown H&E analysis (106and 1006)o f
heart sections from mice treated with PBS (top) or 25 h after LT (100 mg IP) treatment (bottom). Arrows point to the swollen pale cardiomyocytes
seen only in toxin-treated mice. Right panels are TUNEL stain (206) of mouse cardiac tissue from the same untreated (top) and LT-treated (bottom)
mice. Single arrow points to a single TUNEL-positive cell in the untreated control.
doi:10.1371/journal.ppat.1000456.g004
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are elevated with LT treatment
Because nNOS is extremely important in cardiac function (for
reviews see [19–21] we measured the levels of cardiac damage
biomarkers in circulation following toxin treatment. Myoglobin is
one of the first and most sensitive markers for detection of low
levels of myocardial necrosis [22] but because it also exists in
skeletal muscle, it must be used in combination with other heart-
specific markers. Cardiac troponin-I (c-TnI), a regulator of
contractile function, is the universally preferred biomarker for
monitoring cardiotoxicity [23,24] and a wide range of cardiac
injuries [25]. High levels have been shown to appear in
experimental animals from 2–6 h after cardiac injury [24,26].
Heart type fatty acid binding protein (H-FABP) is a highly cardiac
muscle-specific cytoplasmic peptide that can be detected even
earlier than c-TnI [27,28]. We measured myoglobin, c-Tn and H-
FABP protein levels in serum from nNOS2/2 and C57BL/6J
mice at various times post-LT challenge. A rapid dramatic
increase in all three proteins was found in the circulation of LT-
treated nNOS2/2 mice beginning at very early time points, 6–
10 h after toxin treatment (Figure 5A–5C, left panels). Amazingly,
a similar striking early increase in these proteins was also seen in
the WT mice following LT challenge (Figure 5A–5C, right panels).
The cardiac damage demonstrated by these measurements is one
of the earliest events we or others have observed in LT-challenged
WT mice. Protein biomarker levels continued to increase or
remain high in the nNOS2/2 mice until the mice met
moribundity criteria requiring euthanasia (25–36 h) (Figure 5A–
5C, left panels). In the C57BL/6J mice, however, the increased
biomarker concentrations seen in the first 36 h were reversed after
36 h, with an actual reduction to control or below control levels of
these proteins at late time points when the mice showed more
severe malaise symptoms (Figure 5A–5C, right panels). Finding
concentrations of c-TnI exceeding 10 ng/ml in response to LT
treatment was particularly striking, as the maximum published
levels of c-TnI in mice following induced myocardial injury or
toxicity in various studies are 3.5–9 ng/ml [24,26].
Electron microscopy of hearts from LT-treated mice
Based on the clear indications of myocardial injury and because
light microscopy is not sensitive enough for observing changes in
mitochondrial morphology or cardiac endothelium, we performed
electron microscopy on heart sections prepared from untreated,
PA-treated (i.e., a second control) or LT-treated nNOS2/2 and
WT mice. PA-treated mice were not different from untreated
animals at any time point (data not shown). Hearts of untreated
nNOS2/2 mice showed some baseline differences from the WT
animals (Figure 6A), including occasional swelling of sarcoplasmic
reticulum (SR) cisternae and mitochondria (Figure 6B and 6C).
Notably, nNOS2/2 mice at later times (.24 h) after toxin
treatment had distinct and striking pathological changes including
endothelial necrosis, inter-fiber edema with cell debris, altered
endothelial junctions and even fragmented myofilaments
(Figure 6D–6I). Necrotic capillaries were commonly noted in
these mice after LT treatment. Myofilament degeneration with
separation of myofibrils from mitochondria was also observed
(Figure 6G and 6H), clearly indicating cardiomyocyte injury in
LT-treated nNOS2/2 hearts. Surprisingly, the WT mice which
did not exhibit early pathologies did manifest many similar
pathological changes at later times after LT treatment. By 55 h
post-LT treatment, the WT mice showed endothelial cell swelling
and degeneration, altered endothelial junctions, mitochondrial
degeneration/swelling, swollen SR cisternae and myofilament
fragmentation (Figure 6J–6L). Thus, LT clearly affected both
nNOS2/2 and WT hearts in a similar fashion, but with delayed
timing and severity in nNOS-sufficient WT mice. These findings
demonstrate the ability of electron microscopy to detect important
changes that could not be observed in our prior light microscopy
studies and clearly identify the heart as an early LT target in vivo.
Echocardiography of LT-treated hearts
To test cardiac function in LT-treated animals, we performed
echocardiography on nNOS2/2 and WT mice treated with LT
for 24 h compared to untreated controls (Figure S1). Surprisingly,
we found a wide range of variation in the measured parameters for
each test group. As a result, statistically significant differences were
found only between nNOS2/2 and WT animal baseline
parameters, whereas no differences were found between untreated
and LT-treated mice. The left ventricle (LV) end systolic volume
(Vs) and end systolic diameter measurements (Ds) differed
significantly between the nNOS2/2 and WT mice (P=0.0202
and P=0.0176, respectively). The ejection fraction (EF) and
fractional shortening (FS) parameters were also different
(P=0.0325 and 0.0368, respectively), indicative of lower contrac-
tile function in nNOS2/2 mice. The other parameters measured
are identified in the Figure S1 legend. Previous analyses of
nNOS2/2 mice for cardiac function reported no differences in
chamber sizes and basal contractility from those in parental
C57BL/6 mice in the first two months of life (similar age to the
mice used in our studies) with normal baseline ventricular
performance [29]. Later conflicting reports described both
increases and decreases in nNOS2/2 mouse myocyte contractile
function relative to WT mice [29–32]. While the wide variation in
echocardiography measurements for each group in our studies
prevented attainment of statistical significance, a general decreas-
ing trend (based on mean values) in the EF from the LV following
LT treatment in both the knockout and WT mice suggests loss of
contractile function in response to LT. The lack of a more distinct
change in LT-treated animals may simply be related to the
observation that in other animal models, such as the canine model,
EF reductions are only observed at very late time points [33]. Thus
it is possible the manifestations of injury observed by electron
microscopy have to progress further for dysfunction measurable by
echocardiography to occur.
Allopurinol, nitrite, and carboxy-PTIO effects on LT
survival
Since the hearts in LT-treated mice showed severe pathological
changes at early time points, we decided to test therapeutic
approaches used in NO-protective models. We first wanted to test
the role of xanthine oxidoreductase (XOR) in the protection
provided by nNOS against LT. XOR is an enzyme normally
associated with reactive oxygen species (ROS) production in
vascular tissues and the heart [34,35] and its activity is thought to
be directly regulated by nNOS due to their co-localization in the
heart SR [36–38]. ROS produced by XOR can depress
myocardial contractility by inhibiting contractile myofilament
responsiveness to Ca
+2. One of the ways nNOS-derived NO is
thought to be cardioprotective is simply by acting as an anti-
oxidant, scavenging ROS species produced by XOR in the heart
during disease states [38]. Increased XOR activity in the absence
of NO attenuation is associated with the pathophysiology of
cardiac dysfunction [34,39,40] and inhibition of XOR using
allopurinal has previously been shown beneficial for maintaining
normal cardiac and vascular hemodynamics [39]. However since
XOR itself can also act as a source of NO in the heart during
hypoxia, when NOS enzymes are inhibited [35,40], it is also
possible that inhibition of XOR actually results in inhibition of
Anthrax Lethal Toxin Targets the Mouse Heart
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regimen shown effective in inhibiting XOR. Figure 7A shows that
allopurinol treatment does not result in increased survival from
LT, but instead results in a statistically significant exacerbation of
LT effects in C57BL/6J mice, indicating that XOR activity, like
nNOS, serves to protect against LT-mediated effects.
Nitrite therapy has received much attention in recent years as a
cytoprotective therapy in ischemia/reperfusion injury or disease
states associated with NO deficiency [41,42]. Nitrite can be
reduced to NO through numerous mechanisms at many tissue and
cellular sites. We asked whether nitrite therapy could reverse the
detrimental effects of nNOS deficiency in our LT pathogenesis
model. We treated C57BL/6J and nNOS2/2 mice with sodium
nitrite (1 mg/kg mouse, IP) daily for seven days. A single bolus of
LT was injected into the animals on day 2. We did not observe any
statistically significant beneficial effect in mice receiving nitrite
therapy compared to those treated with PBS (Figure 7B). Although
this dose range and IP method of supplying nitrite has proven
Figure 5. Cardiac injury biomarkers myoglobin, cTroponin-I (cTnI), and heart-type fatty acid binding protein (H-FABP) are elevated
after LT treatment of mice. Groups of C57BL/6J (WT) (n=49) and nNOS2/2 mice (n=36) were injected with a single bolus of LT (100 mg IP) and
groups of mice were bled to obtain serum at various time points after injection. Three control animals were treated with PA (100 mg IP) or left
untreated (NT). Levels of myoglobin (A), cTroponin-I (B) and H-FABP (C) were measured for all samples by ELISA. Each symbol represents an individual
mouse; mean measurements for each group are shown.
doi:10.1371/journal.ppat.1000456.g005
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possible that concentrations of NO adequate to protect against LT
were not achieved. Perhaps a direct infusion of nitrite to the heart
would be necessary to show an effect in this situation. On the other
hand, it is possible that lower doses of sodium nitrite than those
used here would be most effective, as has been seen in other cases
[44]. However, experiments using oral delivery of nitrite at a range
of doses, or IP administration of a dose of 0.1 mg/kg/mouse also
did not yield significant benefit (data not shown). Thus it is likely
that nNOS protection against LT is actually mediated through
local, transient and rapid NO gradients that cannot be
compensated through nitrite therapy. Alternatively, nNOS
protective function may also require the reductase function of
the enzyme, and not just the commonly studied oxygenase activity
associated with NO production.
We next wanted to test if systemic scavenging of NO would
result in exacerbation of LT-mediated pathology in WT mice in a
manner similar to the nNOS2/2 mice. Carboxy-PTIO (2-
phenyl-4,4,5,5,-tetramethylimidazoline-1-oxyl-3-oxide) is a potent
NO scavenger which has no direct effect on NO synthase
enzymatic function. We treated WT animals with this drug prior
to LT challenge. Surprisingly, instead of exacerbating LT action,
carboxy-PTIO treatment of WT animals actually had a significant
beneficial effect, prolonging survival of LT-treated mice. Carboxy-
PTIO may provide a protective function in a manner independent
of its NO scavenging ability, or target NO production by other
sources. Thus, NO or other PTIO-scavenged oxidative species
produced at various tissue sites (in a manner independent of
nNOS) may actually have a detrimental effect in LT pathogenesis.
Alternatively, PTIO scavenging of NO may increase activity of
other protective enzymes. The manner in which nNOS provides a
protective role against LT remains to be elucidated.
Discussion
Anthrax LT challenge of mice induces an atypical shock
without classic systemic hemorrhagic manifestations [3]. Histo-
logical studies have revealed only certain pathological changes that
are considered sequelae of vascular insufficiency without providing
clues to the mechanism of shock induction. Vascular dysfunction
makes endothelial cells attractive candidate targets, which is also
consistent with the fact that the two anthrax receptors, TEM8 and
CMG2, are considered to be highly expressed on endothelial cells
[45,46]. Recently our lab has shown that LT targets tumor
angiogenesis [47], further supporting direct LT-mediated effects
on vasculature. Early studies on LT effects on endothelial cells in
vitro reported toxin-mediated human endothelial cell apoptosis
over the course of days [48,49]. Our laboratory and others have
been unable to induce LT-mediated endothelial cell death in vitro
(data not shown and [50]) but endothelial barrier dysfunction is
induced by the toxin in a manner independent of cell death [50].
The data presented here provides the first direct evidence of
profound LT-mediated effects on the heart and specifically on
cardiac vasculature, presenting this organ as a key early target for
LT function.
The heart was also recently suggested as a potential target of LT
in rats [12,51]. While LT is lethal in mice over a course of 2–4
days, some rat strains die in as little as 37 min [4,5]. Studies on
LT-induced shock in toxin-infused rats (which succumb at a slower
rate over 24 h) have also shown shock accompanied by
hypotension, lactic acidosis and an accumulation of pleural fluid,
with no associated histopathological changes, no benefit from fluid
therapy, and therefore, in summary, distinct differences from
classic cytokine-associated endotoxic shock [9,52,53]. Assessment
of vascular function parameters in LT-treated rats pointed to
altered cardiomyocyte function associated with acute heart failure,
suggesting that the rapid and striking pulmonary edema occurs as
a secondary manifestation of the failing heart [12]. Specifically,
rapid myocardial dysfunction in rats was shown as a reduction of
left ventricular systolic function following a single LT bolus
injection [51].
The dramatic pathological changes seen in the mouse heart
following LT treatment in the current study are clearly
independent of macrophage sensitivity and cytokine responses
since C57BL/6J mice harbor LT-resistant macrophage and have
no cytokine responses to LT [3]. These striking effects could be the
result of direct targeting of cardiomyocytes or heart endothelium
by toxin, or once again secondary to LT effects on other cells
controlling peripheral mediators of vasculature homeostasis. The
altered architecture and vacuolation of endothelial cells, however,
is suggestive of direct LT effects on these cells in the heart. It is
important to note that as these LT-induced changes were only
observed by electron microscopy, it is possible that LT also affects
endothelial cells in many other target organs in a similar manner
and even at earlier times. Furthermore, the LT effects reported
here are in the context of a bolus toxin injection model, and it is
more than likely that B. anthracis infections would target numerous
organs earlier during the course of disease, before LT levels
affecting the heart or endothelium are reached. Nonetheless, the
heart damage induced by LT, as measured by rapid and extreme
release of cardiac biomarkers, is the earliest currently known in vivo
effect of this toxin in mice.
An interesting finding in this work is the clear beneficial effect of
nNOS in LT-mediated pathogenesis, while iNOS and eNOS
appear to play no role. NO is a key regulator of vascular function,
affecting blood pressure and flow regulation, platelet aggregation,
and leukocyte adhesion, among others. Although its designation
implies preferential expression in neural tissues, nNOS is actually
Figure 6. Electron microscopy of LT-treated nNOS2/2 and WT mouse hearts. Groups of C57BL/6J (WT) (n=10) and nNOS2/2 mice (n=10)
were injected with a single bolus of LT (100 mg IP) and hearts harvested at 12 h (when both strains show no malaise symptoms) or after moderate to
marked malaise symptoms (28–30 h for nNOS2/2 and 55–60 h for C57BL/6J mice). Three control mice were treated with PA (100 mg IP) or left
untreated (NT). Images representative of each group are shown at differing magnifications as shown by the scale markers. (A) Untreated C57BL/6J
with intact myocytes and endothelium (E=erythrocyte, N=myocyte nucleus). (B–C) Untreated nNOS2/2 mice with swollen sarcoplasmic reticulum
(SR) cisternae (*) and general mitochondrial swelling. (D–I) nNOS2/2 mice, +LT, 28 h: (D) Capillary necrosis (e=endothelial cell) and inter-fiber
edema (*). (E) necrotic capillary with expansion of lumen (c), inter-fiber edema (*), and debris (E= erythrocyte). (F) endothelial necrosis (pyknotic
endothelial nucleus, arrowhead); increased density of endothelial intercellular junction (arrow); fragmented myofilament (*)(e=endothelial cell). (G)
Capillary necrosis (arrow); inter-fiber edema and cell debris (*). (H) shows detail of (G): myofilament degeneration with separation of myofibrils from
mitochondria (**), swollen SR cisternae and transverse (T) tubules (arrow); arrowhead points to lipid. (I) Further detail of (G): endothelial and capillary
necrosis with intraluminal erythrocyte (E) and platelet (P); inter-fiber edema and cell debris (*); (e=endothelial cell). (J–L) C57BL/6J mice+LT, 55 h: (J)
Endothelial cell swelling, mitochondrial degeneration (arrows), multiple swollen SR cisternae (*); M=mitochondria and e=endothelial cell. (K) Detail
of degenerate mitochondrion (arrowhead) and swollen SR (*). (L) Endothelial degeneration; endothelial cytoplasmic swelling with increased
vacuolation; irregular endothelial plasma membrane (e=endothelial cell, arrow marks plasma membrane, arrowhead points to representative
abnormally enlarged cytoplasmic vacuole).
doi:10.1371/journal.ppat.1000456.g006
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as in neurons [54]. However, nNOS-derived NO is believed to
primarily manifest its most potent protective effects in the heart
(for reviews see [19–21,55,56]) and it is possible that the protective
effects of this enzyme after LT treatment are also based on its
function in the heart. All effects of the NO in the heart are
localized paracrine effects dependent on the location of eNOS and
nNOS (the two constitutive enzymes in the heart). This is because
Figure 7. Effects of allopurinol, nitrite therapy, and carboxy-PTIO on LT-induced mortality. (A) Allopurinol treatment: C57BL/6J mice
were gavaged with allopurinol (300 mg/kg, daily, for 5 days) or PBS. One drug-treated group and the PBS-treated controls were injected with LT
(100 mg IP) 2 h after drug/PBS administration on day 2 while a second drug-only control group did not receive toxin. Animals were monitored for
survival (n=5/group). P-value for survival curve of allpurinol/LT vs. PBS/LT is 0.0431. (B) Nitrite Therapy: C57BL/6J and nNOS2/2 mice were injected
with sodium nitrite (1 mg/kg), IP, daily, 7 days) or PBS. A single bolus of LT was injected into mice 2 h after sodium nitrite administration on day 2 and
animals were monitored for survival (n=7 for all groups, except n=10 for the C57BL/6J+LT group). Logrank-test based P-value for nNOS2/2 PBS/LT
vs. nNOS2/2 Nitrite/LT is 0.2928 and P-value for C57BL/6J/PBS/LT vs. C57BL/6J/Nitrite/LT is 0.3907. (C) Carboxy-PTIO treatment. C57BL/6J mice were
injected daily with carboxy-PTIO (100 mg/200 ml/mouse IP) and LT (100 mg) was injected 2 h after drug injection on the second day (n=10 for both
LT-treated groups and n=3 for drug only control group). Logrank-test based P-value comparing the C57BL/6J PTIO/LT survival curve to the LT alone
survival curve is 0.0248.
doi:10.1371/journal.ppat.1000456.g007
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quencher of NO and thus does not allow this normally highly
diffusible molecule to function at distances in the heart. In the
heart eNOS is associated with the caveolae [29,57] and nNOS is
normally in the sarcoplasmic reticulum (SR) in close association
with ryanodine receptors [29,58] and XOR [37,38]. nNOS-
derived NO mediates cardiomyocyte contraction through its
effects on the SR Ca
+2 cycle that is central to excitation-
contraction coupling and modulation of ryanodine receptor
function [21,30–32,59]. NO produced by nNOS is also cardio-
protective by functioning as a local antioxidant which inactivates
the superoxide produced constitutively by the co-localized XOR
[36–38]. As a result, nNOS2/2 mice have 60% higher
superoxide production than WT mice, and this increased ROS
depresses myocardial contractility [38]. We found, however, that
inhibition of XOR had a detrimental effect on survival of LT-
treated WT mice. Interestingly, XOR inhibition with allopurinol
was also unable to reverse the increased susceptibility of nNOS2/
2 mice to this toxin (data not shown) indicating that nNOS was
unlikely to be manifesting its protective functions through
reversing XOR-produced effects.
Multiple explanations can be offered for the protective role of
nNOS against LT. Perhaps the simpler view is that nNOS
deficiency results in an imbalance between oxidative stress and
NO signaling such that the ROS status of the heart leaves it more
susceptible to LT-induced damage. Alternatively, nNOS-derived
NO could be acting to maintain normal cardiomyocyte function,
which serves to counteract the toxin’s deleterious effects on
cardiomyocytes or the peripheral vasculature. In the absence of
nNOS, animals cannot respond as well to LT-mediated cardiac
dysfunction, much as has been noted for other cardiac injury
models. In fact, during cardiac stress or heart failure nNOS has
been shown to translocate to the sarcolemma [60–62] and this
relocalization of nNOS results in a decreased ability to control
contractility via ryanodine receptor [20,21,55]. nNOS and its
activity are upregulated and protective in heart failure. As a result
a higher percentage of nNOS2/2 mice die after induction of
myocardial infarction [60–63].
Despite the appeal of the hypothesis that nNOS protects against
LT by providing improved contractile function in response to
direct or indirect cardiomyocyte damage, it must be noted that
virtually all the reports on the effects of nNOS deficiency on heart
myocytes are contradictory. Basal increase, decrease and lack of
effect on contractility function have been reported for nNOS2/2
mouse myocytes [29–32]. nNOS deficiency effects on ryanodine
receptors in vitro are also contradictory [30,64,65]. Even what
were deemed as the definitive experiments to resolve these
conflicts – namely the tissue-specific over-expression of nNOS in
myocardial tissue, resulted in reduced contractility and reduced
ejection fraction (EF) in one study [66] and increased contractility
and protective function in another [67]. A newer set of MRI
studies on heart function indicated that nNOS does not play a role
in basal contractility, but its absence can have severe effects for b-
adrenergic responses in the heart [68]. It is important to note that
despite the shown LT effects on heart function in LT-sensitive rats,
the potent 7-NI nNOS inhibitor was unable to sensitize LT-
resistant Lewis rats at multiple doses (data not shown), indicating a
genetic-based resistance in rats that differed from the sensitization
seen in mice.
nNOS-derived NO may also provide a protective function
against LT through its control of mitochondrial respiration.
Mitochondrial degeneration was seen in response to LT in mouse
hearts (Figure 4, Figure 6). NO is an inhibitor of cytochrome
oxidase and can act as an antioxidant, protecting against LT-
mediated mitochondrial ROS production [69]. In fact, nNOS2/
2 mice have been shown to have altered respiratory responses
during hypoxia [70] and we know LT induces hypoxia secondary
to vascular collapse [3]. nNOS deletion from the nervous systems
or blood vessels may also result in increased sensitivity to LT.
nNOS has been shown to provide vasculoprotective function at
the vessel level [71,72] and to control microvascular tone [73].
nNOS protective function in endotoxin sepsis, for example, was
postulated to occur through altered cytokine regulation of the
vasculature [14]. Clearly nNOS may provide protection against
LT at multiple tissue sites or due to effects in vasculature in all
organs.
The molecular mechanism(s) by which LT induces the rapid
pathological changes described in this report and the associated
rapid release of cardiac biomarkers (in , 6 h) is unknown. These
are the earliest events yet observed in C57BL/6J mice in response
to LT treatment in the bolus challenge model. The direct
inactivation of key MAPK pathways by the lethal factor protease
may initiate these events. Activation of the MEK1/2 pathway is
considered a protective response in the heart and has been clearly
linked to cardiac hypertrophy in many independent studies,
including those where overexpression of activated MEK1 in
transgenic mice results in dramatic increases in cardiac contractile
performance (for review, see [74]). Furthermore, it has been
reported that the MEK1 pathway is involved in upregulation of
nNOS transcription under some circumstances [75]. With the
known strong links between MEK1/2 activation and cardiopro-
tection, it would be interesting to know whether cleavage and
inactivation of MEK1/2 by LT in the heart leads directly to a loss
of nNOS function. Interestingly, there are several examples of
acute myocarditis and sudden death as a result of rapid proteolytic
cleavage events in the heart caused by infectious agents. Coxsackie
virus destroys cardiomyocytes when its protease 2A cleaves
dystrophin in these cells [76,77] and cardiac NO actually protects
against this cleavage [78]. A recent study reported LT-mediated
breakdown of nNOS in an LT-sensitive macrophage cell line after
toxin treatment [79]. However these dying cells also have the
breakdown of numerous other proteins and the in vitro cleavage of
nNOS by LT in this study required very high ratios of enzyme to
substrate. In this study nNOS activity was also unaffected by LT,
leaving the interpretation of the reported findings uncertain.
Protection against anthrax disease is absolute with neutralizing
antibody against the PA component of anthrax lethal toxin alone.
Thus anthrax toxin is still considered the major relevant virulence
factor for this disease and understanding the mechanisms by which
LT causes mortality and vascular insufficiency can aid in
unraveling the mystery of how this disease kills. We believe the
LT-mediated cardiopathology described here is a step toward a
better understanding of this toxin’s effects in vivo. Our future
studies will focus on deciphering the role the cleavage and
inactivation of MEK proteins may or may not play in LT-induced
cardiomyopathy, the molecular mechanism of LT-induced early
cardiac damage, the means by which nNOS-derived NO is




LF and PA were purified from B. anthracis as previously
described [80]. LF used in this study, like that in all our prior work,
is a recombinant variant having the N-terminal sequence
HMAGG [4]. Toxin was prepared in sterile PBS for animal
injections and in serum-free Dulbecco’s modified Eagle medium
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doses and concentrations correspond to equivalent amounts of
each toxin component (i.e., 100 mg LT is 100 mg PA plus 100 mg
LF). 7-nitroindazole, sodium salt (7-NI, Calbiochem, San Diego,
CA), allopurinol (TCI America, Portland, OR), carboxy-PTIO (2-
phenyl-4,4,5,5,-tetramethylimidazoline-1-oxyl-3-oxide, Cayman
Chemical Company, Ann Arbor, MI) and sodium nitrite
(Mallinckrodt Baker, Phillipsburg, NJ) were used at various doses
as described in each experiment.
Animal studies
C57BL/6J, B6.129SF2/J, and B6.129S4-Nos1
tm1Plh/J
(nNOS2/2) mice (8–12 weeks old, female, 20–25 g) were
purchased from Jackson Laboratories (Bar Harbor, Maine). Age-
matched mice were used for all experiments. For survival studies,
animals were injected intraperitoneally (IP) or intravenously (IV)
with drugs or toxin according to described schedules and observed
for malaise symptoms over time. For cytokine or cardiac
biomarker measurements, mice were bled at various times after
LT injection by cardiac puncture under anesthesia using
microvette serum separator tubes (Sarstedt Inc., Newton, NC).
Mouse tissues (spleen, liver, brain, kidney, heart, lung, femoral
bone) were harvested for histopathological analyses at various
times after LT administration (100 mg IP) and fixed in 10%
neutral buffered formalin, embedded in paraffin and stained with
hematoxylin and eosin (H&E). Selected heart sections were stained
by Masson’s trichrome or immunostained with anti-myeloperox-
idase (DakoCytomation, Glostrup, Denmark and Abcam, Cam-
bridge, MA), anti-nNOS (Zymed Laboratories, San Francisco,
CA) and anti-cytochrome c oxidase I (Santa Cruz Biotech, Santa
Cruz, CA). Terminal deoxynucleotidyl transferase (TdT)-mediat-
ed dUTP-digoxigenin nick end-labeling (TUNEL) was performed
on some heart sections. Staining procedures were performed by
Histoserv Inc. (Gaithersburg, MD). For electron microscopy, heart
sections were fixed in 4% paraformaldehyde/2.5% glutaraldehyde
(Electron Microscopy Sciences, Hatfield, PA) made in PBS
containing 0.05 M sucrose. Tissues were washed twice in 0.1 M
sodium phosphate buffer, pH 7.2, and post fixed in 1% osmium
tetroxide in the same buffer. Following one phosphate buffer wash
and two washes with deionized water, samples were stained with
1% uranyl acetate, dehydrated in ethanol, and embedded in
Spurr’s low viscosity resin (Ted Pella, Inc., Redding, CA). Sections
were cut with a diamond knife and examined at 80 kV, with a
model H7500 transmission electron microscope (Hitachi High
Technologies, America, Pleasanton, CA). Digital images were
collected with an XR-100 camera (Advanced Microscopy
Techniques, Inc., Danvers, MA). For echocardiography studies,
mice were kept under isoflurane anesthesia on a heating pad with
body temperature monitoring (by anal probe) throughout the
procedure. Baseline left ventricular short and long axis views were
obtained with a 30 MHZ RMV 707B mechanical sector
transducer (Visualsonics Inc., Toronto, Canada), with a minimum
of 3 images recorded/animal. All measurements were performed
in blinded fashion.
Cytotoxicity assays
Bone marrow-derived macrophages (BMDMs) from mice were
cultured in differentiation medium consisting of two parts
complete DMEM (10% fetal bovine serum, 10 mM Hepes, and
50 mg/ml gentamicin) and one part L929 cell culture supernatant
(also grown in complete DMEM) for 7 days prior to plating in 96-
well plates for cytotoxicity testing.
Cytokine and cardiac biomarker measurements
ELISA kits for murine IL-1b, MIP1 and IL-6 (R&D systems,
Minneapolis, MN) were utilized for assessment of cytokine levels.
Murine cTroponin-I (cTnI), heart-type fatty acid binding protein
(H-FABP), and myoglobin ELISA kits (Life Diagnostics, West
Chester, PA) were used to measure these cardiac biomarkers in
serum samples. All kits were used according to manufacturer’s
protocols.
Supporting Information
Figure S1 Echocardiography of LT-treated nNOS2/2 and
WT mouse heart. Mice were treated with LT (100 mg IP) and
echocardiography performed at 24–28 h post toxin administra-
tion. Each symbol represents measurements for one mouse and the
mean for each group is also shown. Panels show the following
parameters as measured for LT-treated and untreated knockout
and WT mice: Ds and Dd are the left ventricle end systolic and
diastolic measurements, respectively; Vs and Vd are the left
ventricle-end systolic and diastolic volumes; SV is stroke volume;
EF is ejection fraction; FS is the fractional shortening; CO is the
cardiac output. Left ventricle Vs and Ds differed significantly
between the nNOS2/2 and WT mice (P=0.0202 and
P=0.0176, respectively). Ejection fraction (EF) and fractional
shortening (FS) parameters were also different between these mice
(P=0.0325 and 0.0368, respectively). LT-treated groups were not
statistically different from their untreated counterparts for any
parameter but a decrease in EF values following toxin treatment
was indicative of contractile dysfunction.
Found at: doi:10.1371/journal.ppat.1000456.s001 (0.02 MB PDF)
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